Skip to main content
Top
Published in: Breast Cancer 4/2013

01-10-2013 | Original Article

Pathological assessment of microinvasive carcinoma of the breast

Authors: Miki Mori, Koichiro Tsugawa, Hideko Yamauchi, Hiroshi Yagata, Koyu Suzuki, Sachiko Ohde, Kumiko Soejima, Seigo Nakamura

Published in: Breast Cancer | Issue 4/2013

Login to get access

Abstract

Background

Microinvasive breast cancer (T1mi) is considered as a precursor of invasive cancer developing from ductal carcinoma in situ (DCIS). This study discussed the clinicopathological and immunohistochemical features of T1mi by comparing those of ductal carcinoma in situ (Tis) and T1a to assess the nature and causes of the progression of Tis into invasive cancer.

Methods

Three hundred and ninety-two Tis, 32 T1mi, and 141 T1a lesions which were pathologically diagnosed in surgical specimens between 2006 and 2009 were analyzed retrospectively. T1mi was defined as a tumor no greater than 1 mm in its greatest dimensions, and T1a was defined as a tumor larger than 1 mm but no greater than 5 mm.

Results

The frequency of the comedo type was significantly higher in T1mi (68.8%) than in Tis (13.8%) (p < 0.001) and T1a (30.5%) (p < 0.001). Estrogen receptor (ER) negative–HER2 positive type was more frequent in T1mi (46.9%) than in Tis (8.7%) (p < 0.001) and T1a (10.6%) (p < 0.001). There was a significant difference in Ki-67 index between T1mi (35.2 ± 19.2%) and Tis (18.8 ± 14.5%) (p < 0.001). T1mi had higher rates of comedo type and ER negative–HER2 positive type.

Conclusion

Comedo type and ER negative–HER2 positive type were found more frequently in T1mi than in Tis and T1a. There could be different biological mechanisms for promoting Tis into invasive cancer from enlarging invasive cancer.
Literature
1.
go back to reference Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155–68.PubMed Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155–68.PubMed
2.
go back to reference Nofech-Mozes S, Spayne J, Rakovitch E, Hanna W. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol. 2005;12:256–64.PubMedCrossRef Nofech-Mozes S, Spayne J, Rakovitch E, Hanna W. Prognostic and predictive molecular markers in DCIS: a review. Adv Anat Pathol. 2005;12:256–64.PubMedCrossRef
3.
go back to reference Silverstein MJ, Waisman JR, Gamagami P, Gierson ED, Colburn WJ, Rosser RJ, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer. 1990;66:102–8.PubMedCrossRef Silverstein MJ, Waisman JR, Gamagami P, Gierson ED, Colburn WJ, Rosser RJ, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer. 1990;66:102–8.PubMedCrossRef
4.
go back to reference Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382–90.PubMedCrossRef Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382–90.PubMedCrossRef
5.
go back to reference Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1992;23:961–8.PubMedCrossRef Solin LJ, Fowble BL, Yeh IT, Kowalyshyn MJ, Schultz DJ, Weiss MC, et al. Microinvasive ductal carcinoma of the breast treated with breast-conserving surgery and definitive irradiation. Int J Radiat Oncol Biol Phys. 1992;23:961–8.PubMedCrossRef
6.
go back to reference Simpson T, Thirlby RC, Dail DH. Surgical treatment of ductal carcinoma in situ of the breast: 10- to 20-year follow-up. Arch Surg. 1992;127:468–72.PubMedCrossRef Simpson T, Thirlby RC, Dail DH. Surgical treatment of ductal carcinoma in situ of the breast: 10- to 20-year follow-up. Arch Surg. 1992;127:468–72.PubMedCrossRef
7.
go back to reference Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, et al. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int. 2003;53:422–8.PubMedCrossRef Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, et al. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int. 2003;53:422–8.PubMedCrossRef
8.
go back to reference Slamon DJ, Godolphin W, Jones LA, Koundinya M, Holt JA, Wong SG, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRef Slamon DJ, Godolphin W, Jones LA, Koundinya M, Holt JA, Wong SG, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–12.PubMedCrossRef
9.
go back to reference Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000;19:6115–21.PubMedCrossRef Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 2000;19:6115–21.PubMedCrossRef
10.
go back to reference Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, et al. 14-3-3zeta Cooperates with erb2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial–mesenchymal transition. Cancer Cell. 2009;16:195–207.PubMedCrossRef Lu J, Guo H, Treekitkarnmongkol W, Li P, Zhang J, Shi B, et al. 14-3-3zeta Cooperates with erb2 to promote ductal carcinoma in situ progression to invasive breast cancer by inducing epithelial–mesenchymal transition. Cancer Cell. 2009;16:195–207.PubMedCrossRef
11.
go back to reference Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signaling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11(11):1287–96.PubMedCrossRef Giampieri S, Manning C, Hooper S, Jones L, Hill CS, Sahai E. Localized and reversible TGFbeta signaling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol. 2009;11(11):1287–96.PubMedCrossRef
12.
go back to reference Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N, et al. Tumor-stromal interaction through the estrogen-signalling pathway in human breast cancer. Cancer Res. 2005;65(11):4653–62.PubMedCrossRef Yamaguchi Y, Takei H, Suemasu K, Kobayashi Y, Kurosumi M, Harada N, et al. Tumor-stromal interaction through the estrogen-signalling pathway in human breast cancer. Cancer Res. 2005;65(11):4653–62.PubMedCrossRef
Metadata
Title
Pathological assessment of microinvasive carcinoma of the breast
Authors
Miki Mori
Koichiro Tsugawa
Hideko Yamauchi
Hiroshi Yagata
Koyu Suzuki
Sachiko Ohde
Kumiko Soejima
Seigo Nakamura
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Breast Cancer / Issue 4/2013
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-012-0339-0

Other articles of this Issue 4/2013

Breast Cancer 4/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine